2009 Santa Fe Bone symposium

• Published in: Journal of clinical densitometry Vol. 13; no. 1; p. 1
• Main Authors: Lewiecki, E Michael, Bilezikian, John P, Laster, Andrew J, Miller, Paul D, Recker, Robert R, Russell, R Graham G, Whyte, Michael P
• Format: Journal Article
• Language: English
• Published: United States 01.01.2010
• Subjects: Bone Density Conservation Agents - therapeutic use; Bone Remodeling - drug effects; Congresses as Topic; Fractures, Bone - etiology; Fractures, Bone - prevention & control; Humans; New Mexico; Osteoporosis - complications; Osteoporosis - drug therapy; New Mexico
• ISSN: 1094-6950; 1559-0747
• DOI: 10.1016/j.jocd.2009.12.003

Osteoporosis is a common skeletal disease with serious clinical consequences because of fractures. Despite the availability of clinical tools to diagnose osteoporosis and assess fracture risk, and drugs proven to reduce fracture risk, it remains a disease that is underdiagnosed and undertreated. When treatment is started, it is commonly not taken correctly or long enough to be effective. Recent advances in understanding of the regulators and mediators of bone remodeling have led to new therapeutic targets and the development of drugs that may offer advantages over current agents in reducing the burden of osteoporotic fractures. Many genetic factors that play a role in the pathogenesis of osteoporosis and metabolic bone disease have now been identified. At the 2009 Santa Fe Bone Symposium, held in Santa Fe, New Mexico, USA, the links between advances in genetics, basic bone science, recent clinical trials, and new and emerging therapeutic agents were presented and explored. Socioeconomic challenges and opportunities in the care of osteoporosis were discussed. This is a collection of medical essays based on key presentations at the 2009 Santa Fe Bone Symposium.